From the Department of Cardiology, Başkent University Faculty of Medicine, Ankara, Turkey.
Exp Clin Transplant. 2020 Jan;18(Suppl 1):88-92. doi: 10.6002/ect.TOND-TDTD2019.P32.
Liver transplant is a life-saving procedure for a variety of end-stage liver diseases. Cardiovascular disorders are among the leading cause of death among patients with end-stage liver disease and those undergoing liver transplant procedures. MELD-XI score is a newly developed score for mortality prediction in patients with end-stage liver failure. In this study, we investigated the relationships among MELD-XI score, total in-hospital mortality, and coronary artery disease severity and extent among patients with end-stage liver failure who were awaiting transplant.
We retrospectively reviewed medical records of 121 patients with end-stage liver failure on transplant wait list. Study patients had undergone coronary angiography as part of pretransplant cardiac evaluation. We determined prevalence of coronary artery disease and Gensini score (which indicates extent of coronary artery disease) using coronary angiography and reviewed MELD-XI score and in-hospital mortality rates. We compared MELD-XI score and Gensini score in deceased and surviving patients and correlated both scores with mortality and with each other.
Of 121 patients, 79 (65.3%) were men; mean age of the study population was 59.6 ± 10.2 years. Twenty-eight patients (23.1%) had coronary artery disease, and 13 (10.7%) had severe coronary artery disease on coronary angiography. Twenty-three patients (19%) died while on the transplant wait list. Gensini score and MELD-XI scores were significantly higher in those who died (P < .05). MELD-XI score, but not Gensini score, was a significant independent predictor of death among patients awaiting liver transplant (hazard ratio = 1.35; 95% confidence interval, 1.04-1.78; P < .05).
MELD-XI score independently predicted in-hospital death among patients scheduled to undergo liver transplant. These patients also had increased prevalence and extent of coronary artery disease.
肝移植是治疗各种终末期肝病的一种救命手术。心血管疾病是终末期肝病患者和接受肝移植手术患者死亡的主要原因之一。MELD-XI 评分是一种新开发的用于预测终末期肝功能衰竭患者死亡率的评分。在这项研究中,我们研究了 MELD-XI 评分、总住院死亡率与等待移植的终末期肝功能衰竭患者冠心病严重程度和范围之间的关系。
我们回顾性分析了 121 例等待肝移植的终末期肝功能衰竭患者的病历。研究对象在进行移植前心脏评估时接受了冠状动脉造影。我们通过冠状动脉造影确定了冠心病的患病率和 Gensini 评分(表示冠心病的严重程度),并回顾了 MELD-XI 评分和住院死亡率。我们比较了死亡和存活患者的 MELD-XI 评分和 Gensini 评分,并将这两个评分与死亡率和彼此相关联。
121 例患者中,79 例(65.3%)为男性;研究人群的平均年龄为 59.6±10.2 岁。28 例(23.1%)患者患有冠心病,13 例(10.7%)患者在冠状动脉造影中患有严重冠心病。23 例(19%)患者在等待肝移植期间死亡。死亡患者的 Gensini 评分和 MELD-XI 评分明显较高(P<.05)。在等待肝移植的患者中,MELD-XI 评分而不是 Gensini 评分是死亡的独立预测因素(危险比=1.35;95%置信区间,1.04-1.78;P<.05)。
MELD-XI 评分独立预测了计划接受肝移植的患者的住院内死亡。这些患者还患有更高的冠心病患病率和严重程度。